Efficacy and Safety of Ivarmacitinib in the Treatment of Patients With Polymyalgia Rheumatica

The study intends to explore the efficacy and safety of Ivarmacitinib in therapy for polymyalgia rheumatica through a multicenter, randomized, double-blind, placebo-controlled study, and to explore the effectiveness of Ivarmacitinib as an oral glucocorticoid-sparing alternative in the treatment of polymyalgia rheumatica.

NCT Number	NCT07266168
Lead Sponsor	Second Affiliated Hospital, School of Medicine, Zhejiang University Collaborators: First Affiliated Hospital of Ningbo University, Jinhua Central Hospital, First People's Hospital of Hangzhou, First Affiliated Hospital of Wenzhou Medical University, Huzhou Central Hospital, Ningbo Medical Center Lihuili Hospital, The Second Affiliated Hospital of Jiaxing University, Affiliated Hospital of Jiaxing University, Changxing People's Hospital, Shanghai Zhongshan Hospital, Ruijin Hospital, Qilu Hospital of Shandong University, The First Affiliated Hospital of Nanchang University, RenJi Hospital
Conditions	Polymyalgia Rheumatics (PMR)
Enrollment	80 participants
Start Date	2026-01-20
Primary Completion	2027-12-30 (estimated)
Study Completion	2028-11-30 (estimated)
Updated on ClinicalTrials.gov	2025-12-05